G
George Coukos
Researcher at Ludwig Institute for Cancer Research
Publications - 463
Citations - 49514
George Coukos is an academic researcher from Ludwig Institute for Cancer Research. The author has contributed to research in topics: Ovarian cancer & Immunotherapy. The author has an hindex of 87, co-authored 426 publications receiving 41199 citations. Previous affiliations of George Coukos include Hospital of the University of Pennsylvania & University of Glasgow.
Papers
More filters
Journal ArticleDOI
TIE2-expressing monocytes: a novel cellular biomarker for hepatocellular carcinoma?
TL;DR: This poster presents a probabilistic procedure to characterize the response of the immune system to laser-spot assisted, 3D image analysis of EMMARM, which shows high levels of “good” and “bad” responses.
Journal ArticleDOI
Analysis of Secondary Structure Biases in Naturally Presented HLA-I Ligands.
Marta A S Perez,Marta A S Perez,Michal Bassani-Sternberg,George Coukos,David Gfeller,David Gfeller,Vincent Zoete,Vincent Zoete +7 more
TL;DR: Property analysis of HLA-I binding peptides refines the understanding of the rules governing antigen presentation and could be added to the parameters of the current peptide-MHC class I binding predictors to increase their antigen predictive ability.
Journal ArticleDOI
Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.
Philippe O. Gannon,Alexandre Harari,Alexandre Harari,Aymeric Auger,Clément Murgues,Vincent Zangiacomi,Olivier Rubin,Kim Ellefsen Lavoie,Laurent Guillemot,Blanca Navarro Rodrigo,Blanca Navarro Rodrigo,Tu Nguyen-Ngoc,Sylvie Rusakiewicz,Laetitia Rossier,Caroline Boudousquié,Petra Baumgaertner,Stefan Zimmermann,Lionel Trueb,Emanuela M. Iancu,Christine Sempoux,Nicolas Demartines,George Coukos,George Coukos,Lana E. Kandalaft,Lana E. Kandalaft +24 more
TL;DR: A simplified and efficient method of Tils expansion will enable the broadening of individualized tumor therapy and will increase patients' access to state-of-the-art TILs adoptive cell therapy treatment.
Journal ArticleDOI
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.
Michele Maio,George Coukos,George Coukos,Soldano Ferrone,Bernard A. Fox,Wolf H. Fridman,Patrick L. Garcia,Patrick L. Garcia,Michael Lahn,Olivier Provendier,Vincenzo Russo,Dominik Rüttinger,Aiman Shalabi,Zlatko Trajanoski,Jean Viallet,Jedd D. Wolchok,Ramy Ibrahim +16 more
TL;DR: There remains the need to identify and define genuinely predictive biomarkers to guide treatment and patient selection andCross-specialty and cross-sector collaboration, along with a broader collective data-sharing approach are key to optimizing immuno-oncology therapy in clinical practice.
Journal ArticleDOI
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC.
TL;DR: Schoenfeld et al. as mentioned in this paper combined radiotherapy and immunotherapy for metastatic non-small-cell lung cancer (NSCLC) in the US National Cancer Institute (NCI).